Table 2.

Demographic and clinical details of the study cohort

	Study 1 19 (n = 74)	Study 2 23 (n = 10*)	Study 3 24 (n = 30)	Study 4 (n = 19)	Study 5 (n = 8)	Total (n = 133)
M/F	66/8	9/1*	28/2	15/4	6/2	117/17
Age (years)	61 [27–83]	52 [37–69]	56 [27–82]	63 [34–82]	62 [47–68]	60 [27–83]
Weight (kg)	95 [51–171]	92 [51–126]	93 [63–162]	88 [53–134]	102 [73–156]	94 [51–171]
European ancestry	60	8*	20	17	5	104
Maori/PI	14	2*	8	2	3	27
East Asian ancestry ‡	0	0	1	0	0	1
South Asian ancestry ‡	0	0	1	0	0	1
CLcr (ml min−1)	68 [12–123]	80 [63–105]	67 [53–125]	60 [33–102]	52 [23–78]	68 [12–125]
Diuretics (n [%])	25 [34%]	0*	9 [30%]	4 [21%]	6 [75%]	44 [33%]
β‐adrenoceptor blockers (n [%])	35 [47%]	1* [10%]	8 [27%]	8 [42%]	3 [38%]	54 [41%]
ACEI (n [%])	28 [38%]	3* [30 5]	14 [47%]	6 [32%]	3 [38%]	52 [39%]
ARBs (n [%])	9 [12%]	2* [20%]	2 [7%]	0	2 [25%]	13 [10%]
CCBs (n [%])	17 [23%]	3* [30%]	4 [14%]	2 [11%]	3 [38%]	26 [20%]
Statins (n [%])	34 [46%]	5* [50%]	10 [33%]	6 [20%]	4 [50%]	54 [41%]
NSAIDs (n [%])	12 [16%]	3* [30%]	5 [17%]	–	–	17 [13%]
Uricosuric (n [%])	1 [1.4%]	–	3 [10%]	–	–	4 [3%]
Daily dose (mg)	300 [50–600]	350 [150–500]	200 [50–500]	100 [50–300]	250 [50–700]	300 [50–700]
Oxypurinol (μmol l−1)	114 [15–427]	83 [26–138]	57 [0–198]	11 [0–50]	208 [77–401]	72 [26–427]
Urate (mmol l−1)	0.32 [0.18–0.68]	0.31 [0.20–0.44]	0.41 [0.27–0.63]	0.49 [0.28–0.69]	0.42 [0.30–0.89]	0.38 [0.18–0.89]

All data are expressed as median [range] unless otherwise stated. ACEI, angiotensin converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CCBs, calcium channel blockers; CL_cr, creatinine clearance; M/F, male/female; NSAID, regular use of a non‐steroidal anti‐inflammatory drug; PI, Pacific Islander; statin, HMG‐CoA reductase inhibitors.

^*8 of the 10 patients also participated in the dose‐escalation study (individuals were included once in the total counts);

^‡the subject of Eastern Asian ancestry was Korean, the subject of Southern Asian ancestry was Indian.